Literature DB >> 9767637

A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds.

J E van Muijlwijk-Koezen1, H Timmerman, R Link, H van der Goot, A P Ijzerman.   

Abstract

1-Substituted 3-(2-pyridinyl)isoquinolines have been shown to form a novel class of adenosine A3 receptor ligands. In the present study further investigations of this new lead and the structure affinity relationships of this class of compounds are described. First, the influence of an amide group at position 1 of the isoquinoline ring on the adenosine A3 receptor affinity was determined. A carboxamide proved to be a useful spacer between the isoquinoline and a phenyl ring. N-[2-(2-pyridinyl)isoquinolin-4-yl]benzamide (VUF8507, compound 6) had an affinity of 200 nM at the adenosine A3 receptor. Second, we investigated the effects of substitution of the benzamide ring of 6 with a series of mono- and disubstituted N-[3-(2-pyridinyl)isoquinoline]benzamides. The ratio of the tautomers of the benzamides was determined in the solid state and in solution by spectroscopic techniques (IR and NMR). Affinities were determined in radioligand binding assays at rat brain A1 and A2A receptors and at cloned human A3 receptor. The benzamides showed higher adenosine A3 receptor affinity than aliphatic amides. We propose that the adenosine A3 receptor affinity of the different benzamides is related to their presence in either the iminol or amide form. Ligands present in the iminol form showed relatively high adenosine A3 receptor affinity. Finally, we explored the influence of replacement of C4 of the isoquinoline ring by a nitrogen atom. Comparison of isoquinolines with the corresponding quinazolines revealed that both compounds showed similar adenosine A3 receptor affinity. These investigations led to potent and selective human adenosine A3 receptor ligands with affinities in the nanomolar range. The subtype-selective compound 4-methoxy-N-[2-(2-pyridinyl)quinazolin-4-yl]benzamide (VUF8504, 13) with an affinity of 17.0 nM at the human adenosine A3 receptor might become a useful tool in the pharmacological characterization or the investigation of the physiological function of this receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767637     DOI: 10.1021/jm980037i

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family.

Authors:  T R Webb; N Melman; D Lvovskiy; X D Ji; K A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2000-01-03       Impact factor: 2.823

2.  Chapter 13. A3 Adenosine Receptors.

Authors:  Kenneth A Jacobson; Susanna Tchilibon; Bhalchandra V Joshi; Zhan-Guo Gao
Journal:  Annu Rep Med Chem       Date:  2003       Impact factor: 1.059

3.  Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.

Authors:  Zhan-Guo Gao; Bhalchandra V Joshi; Athena M Klutz; Soo-Kyung Kim; Hyuk Woo Lee; Hea Ok Kim; Lak Shin Jeong; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2005-11-10       Impact factor: 2.823

4.  Functional selectivity of adenosine A1 receptor ligands?

Authors:  Ellen V Langemeijer; Dennis Verzijl; Stefan J Dekker; Ad P Ijzerman
Journal:  Purinergic Signal       Date:  2012-09-28       Impact factor: 3.765

5.  A3 Adenosine Receptors: Protective vs. Damaging Effects Identified Using Novel Agonists and Antagonists.

Authors:  Kenneth A Jacobson; Stefano Moro; Yong-Chul Kim; An-Hu Li
Journal:  Drug Dev Res       Date:  1999-03-01       Impact factor: 4.360

6.  Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors.

Authors:  A H Li; L Chang; X d Ji; N Melman; K A Jacobson
Journal:  Bioconjug Chem       Date:  1999 Jul-Aug       Impact factor: 4.774

Review 7.  Adenosine and ischemic preconditioning.

Authors:  B T Liang; K A Jacobson
Journal:  Curr Pharm Des       Date:  1999-12       Impact factor: 3.116

8.  Pyran Template Approach to the Design of Novel A3 Adenosine Receptor Antagonists.

Authors:  An-Hu Li; Xiao-Duo Ji; Hak Sung Kim; Neli Melman; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  2000-02-11       Impact factor: 4.360

9.  Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors.

Authors:  Thomas R Webb; Dmitriy Lvovskiy; Soon Ai Kim; Xiao duo Ji; Neli Melman; Joel Linden; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2003-01-02       Impact factor: 3.641

Review 10.  Progress in the pursuit of therapeutic adenosine receptor antagonists.

Authors:  Stefano Moro; Zhan-Guo Gao; Kenneth A Jacobson; Giampiero Spalluto
Journal:  Med Res Rev       Date:  2006-03       Impact factor: 12.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.